Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid–induced 2

Cancer Discovery

Volumn 5, Issue 5, 2015, Pages 506-519

  Werner, Stefan ^a   Brors, Benedikt ^b,c   Eick, Julia ^a   Marques, Elsa ^d   Pogenberg, Vivian ^e   Parret, Annabel ^e   Kemming, Dirk ^a,f   Wood, Antony W ^g   Edgren, Henrik ^d   Neubauer, Hans ^h,i   Streichert, Thomas ^a,j   Riethdorf, Sabine ^a   Bedi, Upasana ^a   Baccelli, Irene ^b   Jucker, Manfred ^a   Eils, Roland ^b,k   Fehm, Tanja ^h,i   Trumpp, Andreas ^b   Johnsen, Steven A ^a   Klefstrom, Juha ^d   Wilmanns, Matthias ^e   Muller, Volkmar ^a   Pantel, Klaus ^a   Wikman, Harriet ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c German Consortium for Translational Cancer Research (DKTK)   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^f European Laboratory Association   (Germany)

^g CELL SIGNALING TECHNOLOGY   (United States)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYL TERMINAL BINDING PROTEIN; PROTEIN; REGULATOR PROTEIN; RETINOIC ACID INDUCED 2 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; C-TERMINAL BINDING PROTEIN; DNA BINDING PROTEIN; PROTEIN BINDING; RAI2 PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CELL CULTURE; CELL INVASION; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; METASTASIS; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; AMINO ACID SEQUENCE; BREAST TUMOR; CHEMISTRY; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS; PROTEIN DOMAIN; REPRODUCIBILITY; SEQUENCE ALIGNMENT; TUMOR CELL LINE; TUMOR EMBOLISM;

ALCOHOL OXIDOREDUCTASES; AMINO ACID SEQUENCE; BONE MARROW; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEINS; REPRODUCIBILITY OF RESULTS; SEQUENCE ALIGNMENT; TRANSCRIPTOME;

EID: 84975865416     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1042     Document Type: Article

References (46)

1. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23: 573–81.
2. Lin H, Balic M, Zheng S, Datar R, Cote RJ. Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol 2011; 77: 1–11.
3. Riethdorf S, Pantel K. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 2008; 75: 140–8.
4. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. Apmis 2008; 116: 754–70.
5. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793–802.
6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–10.
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–52.
8. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418–23.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.
10. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 2009; 9: 253–64.
11. Hurst DR, Welch DR. Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol 2011; 286: 107–80.
12. Jonk LJ, de Jonge ME, Vervaart JM, Wissink S, Kruijer W. Isolation and developmental expression of retinoic-acid-induced genes. Dev Biol 1994; 161: 604–14.
13. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–52.
14. Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, et al. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. D evelopment 2 010; 137: 2 045–54.
15. Cieply B, Riley PT, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, et al. Suppression of the epithelial-mesenchymal transition by Grainyheadlike- 2. Cancer Res 2010; 72: 2440–53.
16. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127: 1041–55.
17. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, et al. Towards a proteome-scale map of the human protein–protein interaction network. Nature 2005; 437: 1173–8.
18. Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, et al. Genome-wide profi les of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun 2013; 4: 1449.
19. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 2009; 69: 731–4.
20. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011; 7: 539.
21. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448–56.
22. Woelfl e U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003; 63: 5679–84.
23. Walpole SM, Hiriyana KT, Nicolaou A, Bingham EL, Durham J, Vaudin M, et al. Identifi cation and characterization of the human homologue (RAI2) of a mouse retinoic acid-induced gene in Xp22. Genomics 1999; 55: 275–83.
24. Gattelli A, Cirio MC, Quaglino A, Schere-Levy C, Martinez N, Binaghi M, et al. Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of Wnt pathway activation. Cancer Res 2004; 64: 5193–9.
25. Gattelli A, Zimberlin MN, Meiss RP, Castilla LH, Kordon EC. Selection of early-occurring mutations dictates hormone-independent progression in mouse mammary tumor lines. J Virol 2006; 80: 11409–15.
26. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997; 2: 323–34.
27. Werner S, Frey S, Riethdorf S, Schulze C, Alawi M, Kling L, et al. Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem 2013; 288: 22993–3008.
28. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, et al. Gata-3 is an essential regulator of mammarygland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201–9.
29. Chou J, Lin JH, Brenot A, Kim JW, Provot S, W erb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013; 15: 201–13.
30. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141–52.
31. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ. Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 2002; 277: 47197–204.
32. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 1993; 12: 469–78.
33. Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman RH, Frisch SM. C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci U S A 2003; 100: 4568–73.
34. Grooteclaes ML, Frisch SM. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 2000; 19: 3823–8.
35. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520–9.
36. Center MDAC. Akt inhibitor MK-2206 in patients with advanced breast cancer who have tumors with a PIK3CA mutation and/or PTEN loss. ClinicalTrials.gov2000- [cited 2015 Jan 06].
37. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 1034–9.
38. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012; 18: 1224–31.
39. Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jucker M. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal 2011; 23: 1952–60.
40. Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ. Regulation of human hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic acid signaling. Proc Natl Acad Sci U S A 2013; 110: 16121–6.
41. Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med 2006; 203: 1283–93.
42. Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 2011; 17: 5553–8.
43. Edge SB, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
44. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165–73.
45. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, et al. Genomic profi les associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 2009; 15: 1566–74.
46. Partanen JI, Nieminen AI, Makela TP, Klefstrom J. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci U S A 2007; 104: 14694–9.